That is 0 articles you have read today.
The Aporia is free and carries no advertising, so readers are the only
thing paying for it. If you are getting this much out of it, a small
donation is what keeps it independent.
Daily limit reached
You have read 0 articles today.
That is more than the 15 a day The Aporia gives away,
and well past what it can carry on nothing. Your allowance resets at
midnight.
There is no advertising here and nothing about you is sold, so readers
are the only thing paying for it. If the site is worth this much of
your day, it is worth a few dollars.
Everything else stays open: the
maps, the
directory and
search do
not count against this, and neither does re-opening something you have
already read today.
On September 18, 2026, XORTX Therapeutics Inc., a pharmaceutical company developing therapies for gout and kidney disease, announced plans to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) by the end of 2026 for its drug candidate XRx-026. The submission aims to pave the way for a marketing approval application targeting the $700 million U.S. gout market, based on two-part clinical trials that will assess the pharmacokinetics and efficacy of XORLO™ oxypurinol formulation.
Written locally by qwen2.5:14b on 2026-09-19,
using this article's own text rather than the other coverage of the
same event (that is the story summary below).
Story summary
XORTX Therapeutics Inc., a pharmaceutical company based in Calgary, announced plans to submit an Investigational New Drug application (IND) to the U.S. Food and Drug Administration (FDA) for its XRx-026 gout program by the end of 2026. The company aims to develop XORLO™, a formulation of oxypurinol, as a new therapeutic option targeting the $700 million+ U.S. gout market. To secure FDA marketing approval, XORTX plans to conduct a two-part clinical study to assess the drug's pharmacokinetics and efficacy, followed by manufacturing enough commercial supply for its first year on the market. The company’s efforts include preparing for meetings with the FDA to navigate regulatory requirements effectively.
Written for “XORTX FDA Submission Gout Treatment” on 2026-10-04,
grounded in this article and the 0 other(s) covering the same event.
XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, outlines its anticipated Investigational New Drug application (“IND”) submission to the U.S. Food and Drug Administration (the “FDA”) for the XRx-026 gout program.
asserted
Inc. → focus → program
XORTX’s drug development plan is to seek FDA marketing approval for XRx-026 and provide patients with a new therapeutic option.
asserted
plan → seek → option
The key steps the Company anticipates will be necessary to file a marketing application with the FDA include meetings with the agency, a two-part clinical study to characterize the pharmacokinetics and efficacy of the XORLO™ formulation of oxypurinol, and manufacture of a commercial supply of XORLO™ for the first year of marketing.
asserted
Company → anticipate → marketing
Recent drug development team activities include preparation of a new IND for submission to the FDA in the fourth quarter of 2026.
asserted
activities → include → 2026
The application describes the Company’s clinical development plan and its intention to file a New Drug Application (“NDA”) with the FDA following completion of the planned two-part XRX-OXY-102 clinical trial, which is being advanced based on positive and supportive prior clinical trial results and discussions with the FDA.
asserted
which → describe → FDA
The focus of the XRX-OXY-102 clinical trial is to characterize key information needed by the FDA in its evaluation of a future NDA filing by XORTX for marketing approval.
asserted
focus → characterize → approval
The Aporia
